The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 353:2505-2507 December 8, 2005 Number 23
NextNext

Febuxostat — Treatment for Hyperuricemia and Gout?
Larry W. Moreland, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Becker, M. A.
-PubMed Citation
Gout is a relatively common cause of legendary, severe pain as well as tophi, joint deformities, and nephropathy. Unlike most noninfectious diseases, frequently a pharmacologic "cure" for gout is attained. Shortcomings in the management of gout — due to poor patient education and compliance, substandard medical management, and drug toxicity — can perpetuate its adverse effects. The burden of gout is substantial, and recent epidemiologic studies suggest that it is increasing. This increase is probably due to risk factors related to lifestyle.1,2

Acute and chronic arthritis, tophi, and renal disease are manifestations of gout that reflect the magnitude and duration . . . [Full Text of this Article]


Source Information

From the University of Alabama at Birmingham School of Medicine, Birmingham.




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.